HCW Biologics
HCWB
13 hedge funds and large institutions have $1.93M invested in HCW Biologics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
8% more funds holding
Funds holding: 12 → 13 (+1)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
11% less capital invested
Capital invested by funds: $2.17M → $1.93M (-$239K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.97K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.98K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$495 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$495 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$7.91K |
| 2 |
BlackRock
New York
|
-$3.96K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
HighTower Advisors
Chicago,
Illinois
| $675K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $389K | +$36.1K | +73 | +9% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $253K | +$2.97K | +6 | +1% |
|
|
CAM
4
Cresset Asset Management
Chicago,
Illinois
| $251K | – | – | – |
|
|
BCM
5
Bridgeway Capital Management
Houston,
Texas
| $158K | – | – | – |
|
|
6
BlackRock
New York
| $90.7K | -$3.96K | -8 | -4% |
|
|
7
Two Sigma Investments
New York
| $43.4K | -$7.91K | -16 | -14% |
|
8
State Street
Boston,
Massachusetts
| $41K | – | – | – |
|
9
Northern Trust
Chicago,
Illinois
| $19.4K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $8.86K | +$1.98K | +4 | +27% |
|
|
FWM
11
Focused Wealth Management
Newburgh,
New York
| $1.9K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $403 | +$495 | +1 | New |
|
|
13
Wells Fargo
San Francisco,
California
| $249 | +$495 | +1 | New |
|
14
JP Morgan Chase
New York
| $42 | – | – | – |
|
HCWB Hedge Fund Activity: Q3 2023 in Review
13 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q3 2023, worth a combined $1.93M — down 11% from $2.17M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HCWB positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $36.1K. The largest seller was Two Sigma Investments, cutting an estimated $7.91K.
- 13 institutional investors held HCW Biologics (HCWB) as of Q3 2023, up from 12 in Q2 2023.
- Funds reported $1.93M of HCW Biologics stock for Q3 2023, down 11% quarter-over-quarter.
- 2 funds opened new HCW Biologics positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest HCW Biologics buyer in Q3 2023 was Vanguard Group, an estimated $36.1K added.
- The largest HCW Biologics seller in Q3 2023 was Two Sigma Investments, an estimated $7.91K sold.
Based on aggregated 13F filings for Q3 2023.